Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer
10 juin 2024 10h17 HE
|
Sermonix Pharmaceuticals Inc.
In preclinical mouse models, results suggested lasofoxifene could be an effective therapy for all hormone treatment-resistant breast tumorsPhase 3 ELAINE-3 study is currently investigating...
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
10 juin 2024 08h55 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will...
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
10 juin 2024 07h00 HE
|
TransCode Therapeutics, Inc.
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
Cumulus Oncology Appoints Catherine Lewis La Torre to its Board of Directors
10 juin 2024 04h00 HE
|
Cumulus Oncology
EDINBURGH, Scotland, June 10, 2024 (GLOBE NEWSWIRE) -- Cumulus Oncology, Europe’s first oncology-focused biotech company creation factory, announces the appointment of Catherine Lewis La Torre to...
Macomics Announces Appointment of Simon Dew as New Chief Business Officer
10 juin 2024 04h00 HE
|
Macomics Limited
Macomics continues to expand its leadership team to accelerate the development of first-in-class macrophage-targeted therapiesSimon Dew brings over 25 years of experience in pharmaceutical business...
Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing
10 juin 2024 01h00 HE
|
Biocartis NV
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV...
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
07 juin 2024 15h32 HE
|
Tevogen Bio Inc
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
06 juin 2024 18h14 HE
|
Tevogen Bio Inc
Tevogen social event aimed to understand patients' needs and discuss how its model could reduce healthcare costs and improve patient outcomes.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
06 juin 2024 12h14 HE
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
Sermonix Pharmaceuticals Announces Chinese Approval of Investigational New Drug Application for Lasofoxifene
06 juin 2024 09h00 HE
|
Sermonix Pharmaceuticals Inc.
IND approval in China allows Shanghai Henlius Biotech, Sermonix’s Chinese development partner for oral lasofoxifene, to enroll ELAINE-3 trial patients in ChinaUnder strategic collaboration agreement...